Deciphering molecular mechanisms underlying chemoresistance in relapsed AML patients: towards precision medicine overcoming drug resistance

Deciphering molecular mechanisms underlying chemoresistance in relapsed AML patients: towards precision medicine overcoming drug resistance

Abstract Background Acute myeloid leukemia (AML) remains a devastating disease with a 5-year survival rate of less than 30%. AML treatment has undergone significant changes in recent years, incorporating novel targeted therapies along with improvements in allogeneic bone marrow transplantation techn...

Full description

Bibliographic Details
Main Authors: May Levin, Michal Stark, Yishai Ofran, Yehuda G. Assaraf
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Cancer Cell International
Subjects:
AML
Chemotherapy
Intrinsic/acquired chemoresistance
Resistance modalities
Drug metabolism
Relapse
Online Access:https://doi.org/10.1186/s12935-021-01746-w

Internet

https://doi.org/10.1186/s12935-021-01746-w

Similar Items